Results 11 to 20 of about 6,247 (199)

Impact of signs and symptoms on the prognosis of patients with HFmrEF

BMC Cardiovascular Disorders, 2023
Abstract Background Worsening of heart failure (HF) symptoms is the leading cause of medical contact and hospitalization of patients with mildly reduced ejection fraction (HFmrEF). The prognostic value of signs and symptoms for patients with HFmrEF is currently unclear.
Zhican Liu, Yunlong Zhu, Lingling Zhang, Mingxin Wu, Haobo Huang, Ke Peng, Wenjiao Zhao, Sihao Chen, Xin Peng, Na Li, Hui Zhang, Yuying Zhou, Yongliang Chen, Sha Xiao, Liqing Yi, Jie Fan, Jianping Zeng   +16 more
openaire   +4 more sources

Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF [PDF]

JACC: Heart Failure, 2023
في حين أنه لا يوصى باستخدام حاصرات بيتا لعلاج HFpEF وفقًا لأحدث إرشادات ESC و AHA/ACC/HFSA، إلا أن هذه العلاجات لا تزال شائعة الاستخدام لإدارة الاعتلال المشترك. كان هناك قلق من أن حاصرات بيتا قد تؤثر سلبًا على النتائج السريرية من خلال الحد من الاستجابة الكرونوتروبية في HFpEF.
Alexander Peikert, Bradley A. Bart, Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Mikhail Kosiborod, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon, Orly Vardeny   +18 more
openaire   +2 more sources

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes [PDF]

Frontiers in Cardiovascular Medicine, 2021
Traditionally, patients with heart failure (HF) are divided according to ejection fraction (EF) threshold more or <50%. In 2016, the ESC guidelines introduced a new subgroup of HF patients including those subjects with EF ranging between 40 and 49% called heart failure with midrange EF (HFmrEF).
Palazzuoli A., Beltrami M.
openaire   +7 more sources

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF [PDF]

International Journal of Heart Failure
Heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent over half of heart failure cases but lack proven effective therapies beyond sodium-glucose cotransporter 2 inhibitor and diuretics. HFmrEF and HFpEF are heterogeneous conditions requiring precision phenotyping to enable tailored therapies.
Giuseppe M.C. Rosano, Cristiana Vitale, Ilaria Spoletini   +2 more
openaire   +3 more sources

Acute heart failure with mildly reduced ejection fraction and myocardial infarction: a multi-institutional cohort study

BMC Cardiovascular Disorders, 2023
Background Little research has been done on ischemic outcomes related to left ventricular ejection fraction (EF) in acute decompensated heart failure (ADHF).
Ming-Shyan Lin, Po-Chang Wang, Meng-Hung Lin, Ting-Yu Kuo, Yu-Sheng Lin, Tien-Hsing Chen, Ming-Horng Tsai, Yao-Hsu Yang, Chun-Liang Lin, Chang-Min Chung, Pao-Hsien Chu   +10 more
doaj   +2 more sources

Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF

JACC: Heart Failure, 2018
The purpose of this study was to assess the association between N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiovascular (CV) versus non-CV events and between NT-proBNP and potential treatment effects in heart failure (HF) with preserved, mid-range, and reduced ejection fraction (HFpEF, HFmrEF, and HFrEF, respectively) and clinically ...
Savarese G, Orsini N, Hage C, Vedin O, Cosentino F, Rosano GMC, Dahlström U, Lund LH   +7 more
openaire   +4 more sources

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction [PDF]

Diagnostics, 2022
Data on the relevance of anemia in heart failure (HF) patients with an ejection fraction (EF) > 40% by subgroup—preserved (HFpEF), mildly reduced (HFmrEF) and the newly defined recovered EF (HFrecEF)—are scarce.
Anita Pintér, Anett Behon, Boglárka Veres, Eperke Dóra Merkel, Walter Richard Schwertner, Luca Katalin Kuthi, Richard Masszi, Bálint Károly Lakatos, Attila Kovács, Dávid Becker, Béla Merkely, Annamária Kosztin   +11 more
doaj   +2 more sources

Heart Failure with Mildly Reduced Ejection Fraction—A Phenotype Waiting to Be Explored

Journal of Cardiovascular Development and Disease
Heart failure (HF) presents a significant global health challenge recognised by frequent hospitalisation and high mortality rates. The assessment of left ventricular (LV) ejection fraction (EF) plays a crucial role in diagnosing and predicting outcomes ...
Anugrah Nair, Lukah Q. Tuan, Natasha Jones-Lewis, Deep Chandh Raja, Jenish Shroff, Rajeev Kumar Pathak   +5 more
doaj   +2 more sources

Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF

JACC: Heart Failure
Chronic kidney disease (CKD) is defined by the KDIGO (Kidney Disease: Improving Global Outcomes) guideline as abnormal kidney structure or function, present for >3 months, with implications for health. KDIGO-defined CKD is associated with poor outcomes in patients with heart failure (HF).
Samir Patel, Venkatesh K. Raman, Charles Faselis, Gregg C. Fonarow, Phillip H. Lam, Amiya A. Ahmed, Paul A. Heidenreich, Stefan D. Anker, Prakash Deedwania, Charity J. Morgan, Sijian Zhang, Hans Moore, Janani Rangaswami, George Bakris, Javed Butler, Helen M. Sheriff, Richard M. Allman, Qing Zeng-Treitler, Wen-Chih Wu, Ali Ahmed   +19 more
openaire   +4 more sources

Heart Failure with Mid-Range Ejection Fraction - State of the Art

Arquivos Brasileiros de Cardiologia, 2019
In 2016, the European Society of Cardiology (ESC) recognized heart failure (HF) with ejection fraction between 40 and 49% as a new HF phenotype, HF with mid-range ejection fraction (HFmrEF), with the main purpose of encouraging studies on this new ...
Evandro Tinoco Mesquita, Letícia Mara dos Santos Barbetta, Eduardo Thadeu de Oliveira Correia   +2 more
doaj   +2 more sources